The TRICs up Lung Cancer's Sleeve
With Unique MOA, HER4 Joins EGFR Family Cancer Targets
By Anette Breindl
Wednesday, February 6, 2013
Studying cancer cells that survive chemotherapy treatment, scientists from Roche AG subsidiary Genentech Inc. have implicated a member of the human epidermal growth factor receptor, or HER, family in such treatment resistance.In their experiments, senior author Erica Jackson and her team looked at mouse models of non-small-cell lung cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.